Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI

The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is standard therapy for head and neck squamous cell carcinoma (HNSCC). However, most HNSCC tumors are resistant to it and require alternative treatments. Here, we explored the mechanism of cetuximab resistance and evaluated its clin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogenesis
Hauptverfasser: Yonesaka, Kimio, Tanaka, Kaoru, Kitano, Mutsukazu, Kawakami, Hisato, Hayashi, Hidetoshi, Takeda, Masayuki, Sakai, Kazuko, Nishio, Kazuto, Doi, Katsumi, Nakagawa, Kazuhiko
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6769016/
https://ncbi.nlm.nih.gov/pubmed/31570699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-019-0164-9
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge